Involvement of soluble receptor activator of nuclear factor-κB ligand (sRANKL) in collagenase-induced murine osteoarthritis and human osteoarthritis

Rheumatology International

Volumn 32, Issue 5, 2012, Pages 1317-1325

  Dimitrova, Petya ^a   Toncheva, Antoaneta ^b   Gyurkovska, Valeriya ^a   Ivanovska, Nina ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^b National Transport Hospital   (Bulgaria)

Author keywords

Collagenase induced osteoarthritis; Neutrophils; Osteoarthritis; SRANKL

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; COLLAGEN; COLLAGENASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEOGLYCAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REMODELING; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYNOVIUM; UPREGULATION;

AGED; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE REMODELING; BULGARIA; CASE-CONTROL STUDIES; COLLAGEN; COLLAGENASES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; JOINTS; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEUTROPHILS; OSTEOARTHRITIS; RANK LIGAND; SYNOVIAL MEMBRANE; TIME FACTORS; UP-REGULATION;

EID: 84863634907     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1723-8     Document Type: Article

References (28)

1. Brandt KD (2003) Osteoarthritis. Preface. Rheum Dis Clin North Am 29:ix-xiii. doi:10.1016/S0889-857X(03)00076-0
2. Yasuda H, Shima N, Nakagawa N, Yamaguchi K et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602. doi:10.1073/pnas.202332999
3. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504-1508. doi:10.1126/science.289.5484.1504
4. Li J, Sarosi I, Yan XQ et al (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclasto-genesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571
5. Naito A, Azuma S, Tanaka S et al (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4:353-362. doi:10.1046/j.1365-2443.1999.00265.x
6. Franzoso G, Carlson L, Xing L et al (1997) Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11:3482-3496. doi:10.1101/gad.11. 24.3482
7. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S (1998) Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250:776-781. doi:10.1006/bbrc.1998.9394
8. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275:768-775. doi:10.1006/bbrc.2000.3379
9. Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, Tak PP, Haynes DR (2002) Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61:1047-1054. doi:10.1136/ard.61.12.1047
10. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250-258. doi:10.1002/1529- 0131(200002)43:2\250:AID-ANR3[3.0.CO;2-P
11. Ji H, Pettit A, Ohmura K et al (2002) Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196:77-85. doi:10.1084/jem.20020439
12. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025-4031
13. Kamijo S, Nakajima A, Ikeda K, Aoki K, Ohya K, Akiba H, Yagita H, Okumura K (2006) Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun 347:124-132. doi: 10.1016/j.bbrc.2006.06.098
14. Bekker PJ, Holloway DL, Rasmussen AS et al (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066. doi:10.1359/JBMR.040305
15. Santos LL, Morand EF, Hutchinson P, Boyce NW, Holdsworth SR (1997) Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. Clin Exp Immunol 107:248-253. doi:10.1111/j.1365-2249.1997.263- ce1154.x
16. Chakrabarti S, Patel KD (2005) Regulation of matrix metallo-proteinase-9 release from IL-8-stimulated human neutrophils. J Leukoc Biol 78:279-288. doi:10.1189/jlb.1004612
17. Felzmann T, Gadd S, Majdic O, Maurer D, Petera P, Smolen J, Knapp W (1991) Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis. J Clin Immunol 11:205-212
18. Pronai L, Ichikawa Y, Ichimori K, Nakazawa H, Arimori S (1991) Association of enhanced superoxide generation by neu-trophils with low superoxide scavenging activity of the peripheral blood, joint fluid, and their leukocyte components in rheumatoid arthritis: effects of slow-acting anti-rheumatic drugs and disease activity. Clin Exp Rheumatol 9:149-155
19. Kragstrup TW, Otkjaer K, Holm C, Jorgensen A, Hokland M, Iversen L, Deleuran B (2008) The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine 41:16-23. doi:10.1016/j.cyto. 2007.10.004
20. Shen F, Ruddy MJ, Plamondon P, Gaffen SL (2005) Cytokines link osteoblasts and inflammation: microarray analysis of inter-leukin-17-and TNF-alpha-induced genes in bone cells. J Leukoc Biol 77:388-399. doi:10.1189/jlb.0904490
21. Poubelle PE, Chakravarti A, Fernandes MJ, Doiron K, Marceau AA (2007) Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res Ther 9:R25. doi:10.1186/ar2137
22. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, Salter D, van den Berg WB (2006) Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 14:13-29. doi:10.1016/j.joca.2005. 07.014
23. Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoproteg-erin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
24. Daans M, Lories RJ, Luyten FP (2008) Dynamic activation of bone morphogenetic protein signaling in collagen-induced arthritis supports their role in joint homeostasis and disease. Arthritis Res Ther 10:R115. doi:10.1186/ar2518
25. Ikeda T, Kasai M, Utsuyama M, Hirokawa K (2001) Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 142:1419-1426
26. Gonzalez-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, Laffon A, Garcia-Vicuna R (2007) Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis 66:1675-1678. doi:10.1136/ard.2007.071910
27. Pilichou A, Papassotiriou I, Michalakakou K, Fessatou S, Fan-dridis E, Papachristou G, Terpos E (2008) High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem 41:746-749. doi:10.1016/j.clinbiochem.2008.02. 011
28. Toncheva A, Remichkova M, Ikonomova K, Dimitrova P, Ivanovska N (2009) Inflammatory response in patients with active and inactive osteoarthritis. Rheumatol Int 29:1197-1203. doi:10.1007/s00296-009-0864-0